MaxiVAX SA

Swiss Biotech Association

Not a member

MaxiVAX SA is a clinical stage (Phase II) biotech company dedicated to the cure of cancer by immuno-therapy.

http://www.maxivax.ch/

Location

Rue de l'Athénée 24, 1206 Geneva, Switzerland

Facts & figures

Type of organization

Private company
Year of foundation

2005
Number of employees in Switzerland

1-9

Key business

Core competencies

You may also be interested in

SIX

The Swiss Stock Exchange, representing more than a third of the European life sciences market capitalization and accounting for around 35% of the total market capitalization (as of 7 April 2021), the exchange is one of Europe’s leading listing venues for biotech companies.
Zürich

Laevoroc Oncology AG

Founded in 2019, Laevoroc is a privately-owned, Swiss oncology group of companies that leverages word-class technologies, our oncology expertise and extensive R&D and commercial experience to approach innovation in cancer therapeutics in a way that combines the pragmatic with the visionary.
Hünenberg

Rowestil Consulting GmbH

Expertise in exploratory clinical drug/diagnostic development is available across a number of disease areas. Timing of input into the developmental strategy from regulatory and commercial perspectives is important in moving development programs towards success.
6318 Walchwil